SEARCH

SEARCH BY CITATION

References

  • 1
    Nimmerjahn F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513533.
  • 2
    Brandt D, Gershwin ME. 2006. Common variable immune deficiency and autoimmunity. Autoimmun Rev 5: 465470.
  • 3
    Jordan SC, Toyoda M, Vo A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 16.
  • 4
    Durandy A, Kaveri S, Kuijpers T et al. Intravenous Immunoglobulians—Understanding Properties and Mechanisms. Clin Exp. Immunology 2009; 158: 213.
  • 5
    Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800805.
  • 6
    Casadei DH, del C Rial M, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 5358.
  • 7
    Jordan SC, Reinsmoen N, Peng A et al. Advances in diagnosis and managing antibody-mediated rejection. Pediatr Nephrol 2010; 25: 20352045.
  • 8
    Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly-HLA sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 32563262.
  • 9
    United Network for Organ Sharing (UNOS) (unos.org). August 7, 2010.
  • 10
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin pro- vides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 11
    Shehata N, Palda V, Meyer R et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence -based practice guideline. Transf Med Rev 2010; 24: 727.
  • 12
    Nahirniak S, Hume H. Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev 2010; 24: 16. 6.
  • 13
    Peraldi MN, Akposso K, Haymann JP et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996; 62: 16701673.
  • 14
    Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 88: 444.
  • 15
    Bachler K, Amico P, Honger G et al. Efficacy of induction therapy with ATG and intravenous immunoglobulin in patients with low-level donor specific HLA antibodies. Am J Transplant 2010; 10: 12541262.
  • 16
    Thielke JJ, West-Thielke PM, Herren HL et al. Living donor kidney transplantation across positive crossmatch: The university of illinois at chicago experience. Transplantation 2009; 87: 268273.
  • 17
    Magee C, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: One center's experience. Transplantation 2008; 86: 96103.
  • 18
    Vo A, Lukovsky M, Toyoda M et al. Rituximab and Intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242251.
  • 19
    Vo A, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 10951102.
  • 20
    Loupy A, Suberbielle-Boissel C, Zuber J et al. Combined posttransplant prophylactic IVIg/anti-CD20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 14031407.
  • 21
    Udl N, Shoenfeld Y. Intravenous immunoglobulin-indications and mechanisms in cardiovascular disease. Autoimmun Rev 2008; 7: 445452.
  • 22
    Pisani BA, Mullen GM, Malinowska K et al. Plasma- pheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701706.
  • 23
    John R, Lietz K, Burke E et al. Intravenous immuno- globulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100(19 Suppl): II229II235.
  • 24
    Appel III JZ, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005; 66: 378386.
  • 25
    Hachem R, Yusen R, Meyers B et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973980.
  • 26
    Lefaucher G, Nochy D, Andrade J et al. Comparison of combination plasmapheresis/IVIG/Anti-CD20 versus high dose IVIG in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 10991107.
  • 27
    Vo A, Lee R, Lin J et al. Comparison of induction therapy with campath 1H vs Zenapax® in Highly-HLA Sensitized Patients (HS) transplanted after desensitization With IVIG+Rituximab. Am J Transplantation 2010; 10: 317.
  • 28
    Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 6373.
  • 29
    Kessler L, Parissiadis A, Bayle F et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009; 9: 19611966.
  • 30
    Manhorter S, Yamani M. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13: 581585.
  • 31
    Smith J, Jordan SC. IVIG As treatment for BK virus nephropathy. Pediatr Transplant 2008; 13: 1113.
  • 32
    Rhada R, Jordan SC, Puliyanda D et al. Cellular immune response to CMV in renal transplant recipients. Am J Transplant 2005; 5: 110117.
  • 33
    Shen Q, Xu H, Cao Q et al. Long-term remission of recurrent parvovirus B19 infection in a pediatric renal transplant recipient. Pediatr Transplant 2010; Epub ahead of print.
  • 34
    Barsoum N, Bannapradist S, Moudgil A, Toyoda M, Vo A, Jordan SD. Treatment of parvovirus B-19 infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2002; 2: 425428.
  • 35
    Potena L, Holweg CT, Chin C et al. Acute rejection and cardiac allograft vascular disease reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82: 398405.
  • 36
    Vo AA, Cam V, Toyoda M et al. Safety and adverse events profiles of IVIG products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 2006; 4: 844852.
  • 37
    Kahwaji J, Baker E, Pepkowitz S et al. Acute hemolysis after high dose IVIG therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 24: 155160.